Novartis AG’s pioneering new cancer drug on Wednesday won enthusiastic support from a US federal advisory panel, paving the way for approval of the first US gene therapy.
The panel unanimously recommended that the US Food and Drug Administration (FDA) approve the drug — tisagenlecleucel — for patients ages three to 25 with relapsed B-cell acute lymphoblastic leukemia (ALL), the most common form of US childhood cancer.
The drug uses a new technology known as CAR-T, or chimeric antigen receptor T-cell therapy, which harnesses the body’s own immune cells to recognize and attack malignant cells.
Photo: AP
In a clinical trial, 83 percent of patients who had relapsed or failed chemotherapy achieved complete or partial remission three months post infusion. After one year 79 percent of patients were still alive.
Patients with ALL who fail chemotherapy typically have only a 16 percent to 30 percent chance of survival.
“This is a potentially paradigm-changing type of benefit,” said Brian Rini, one of the panelists and a physician at Cleveland Clinic Taussig Cancer Institute.
The FDA is not obliged to follow the recommendations of its advisers, but typically does so. The agency is expected to rule on the drug by the end of September.
Approval of tisagenlecleucel would have implications not only for Novartis, but for companies developing similar treatments, including Kite Pharma Inc, Juno Therapeutics Inc and bluebird bio Inc.
It would also advance a technique scientists have been attempting to perfect for decades and help lift the entire field of cell therapy.
“This will be a historic approval,” said Brad Loncar, chief executive of Loncar Investments, which runs the Loncar Cancer Immunotherapy ETF. “As an investor I’ve never seen anything like it. It’s an entirely new way of treating cancer.”
The product is made by extracting and isolating a patient’s T cells, genetically engineering them to recognize and target cancer cells, and then infusing them back into the patient.
Novartis said the entire process would take 22 days by the time it is launched.
The treatments are given just once and are expected to cost up to US$500,000.
Loncar said approval of tisagenlecleucel would represent an inflection point for investors.
“Any time a new technology crosses the finish line at the FDA, it gets noticed and I think you’ll see a rush of investment and see these therapies be improved over time,” Loncar said.
More than half of patients experienced a serious complication known as cytokine release syndrome, which occurs when the body’s immune system goes into overdrive. Doctors were able to manage the condition and the syndrome caused no deaths.
The FDA expressed concern that the drug could cause new malignancies over the long term.
Panelists generally felt that risk was low and they said Novartis’ risk mitigation proposals were adequate.
Novartis is also testing the drug in diffuse large B-cell Lymphoma, the most common form of non-Hodgkin lymphoma, as is Kite.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day